Cabaletta Bio, Inc. (CABA)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Cabaletta Bio, Inc. (CABA)
Go deeper and ask any question about CABA
Company Performance
Current Price
as of Sep 13, 2024$4.11
P/E Ratio
N/A
Market Cap
$200.77M
Description
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
Metrics
Overview
- HQPhiladelphia, PA
- SectorHealth Technology
- IndustryBiotechnology
- TickerCABA
- Price$4.11+1.99%
Trading Information
- Market Cap$200.77M
- Float84.22%
- Average Daily Volume (1m)877,053
- Average Daily Volume (3m)1,197,857
- EPS-$1.91
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$27.60M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$29.85M
- EV$174.03M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account
Factset